Melanoma/Skin Cancer News

The use of genetic expression profiling (GEP) assays is standard of care for the management of many cancers, including breast, prostate and thyroid cancers, and uveal melanoma. They are coming into standard use for melanoma.

The past decade has ushered in major transformations in the prevention, diagnosis and treatment of melanoma.

Mutational heterogeneity was observed in almost 20% of melanoma tumors, according to a study.

A randomized phase 3 trial designed to evaluate the addition of spartalizumab to two targeted agents for the treatment of certain patients with advanced melanoma failed to meet its primary endpoint, according to the agent’s manufacturer.

Patrick Hwu, MD, has been appointed president and CEO of Moffitt Cancer Center.

Nivolumab plus ipilimumab- and pembrolizumab-based therapies may be the most cost-effective approaches in advanced melanoma, according to a study.

Pembrolizumab induced clinically meaningful and durable responses among elderly patients with recurrent or metastatic cutaneous squamous cell carcinoma, according to study results published in Journal of Clinical Oncology.

Consumption of caffeinated coffee does not appear to increase risk for various cancer types, according to a review article published in The New England Journal of Medicine.

Cancer-related patient encounters have decreased significantly as a result of the COVID-19 pandemic, according to trends observed in the COVID and Cancer Research Network and reported in JCO: Clinical Cancer Informatics.

Parker Institute for Cancer Immunotherapy appointed John Connolly, PhD, as its chief scientific officer.